OncoMatch/Clinical Trials/NCT06196294
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
Is NCT06196294 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Cell therapy for solid tumors for pancreas cancer.
Treatment: Cell therapy for solid tumors — The third generation of GPC3/mesothelin targeted CAR-γδT cells have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-γδT cells for immunotherapy of human cancer patients with GPC3 or Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/Mesothelin-CAR-γδT cell immunotherapy on human cancers will firstly be evaluated.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Hepatocellular Carcinoma
Mesothelioma
Tumor Agnostic
Biomarker criteria
Required: GPC3 overexpression
cancer that expresses GPC3 or Mesothelin protein
Required: MSLN overexpression
cancer that expresses GPC3 or Mesothelin protein
Demographics
Prior therapy
Cannot have received: gene therapy
Lab requirements
Blood counts
adequate blood function
Kidney function
adequate kidney function
Liver function
adequate liver function
Cardiac function
adequate heart function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06196294 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene therapy disqualifies patients from enrollment.
Does this trial require GPC3?
Yes, GPC3 overexpression is a required biomarker for enrollment.
Does this trial require MSLN?
Yes, MSLN overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify